Treatment of cutaneous leishmaniasis with either topical paromomycin or intralesional meglumine antimoniate
Treatment of cutaneous leishmaniasis with either topical paromomycin or intralesional meglumine antimoniate
复制标题
DOI：
10.1046/j.1365-2230.2003.01169.x
复制
发表时间：
2003-01-01
影响因子：
4.1
通讯作者：
Tavakoli-kia, R
中科院分区：
文献类型：
--
作者：
Faghihi, G;Tavakoli-kia, R
96例临床和寄生虫学诊断为皮肤利什曼病的患者被招募到一项比较随机临床试验中，评价局部巴龙霉素与每周一次病灶内注射锑酸葡甲胺的疗效。将患者随机分为两组：一组外用巴龙霉素软膏，另一组病灶内注射锑酸葡胺。在两组中继续治疗，直到完全恢复（定义为在不到2个月内愈合，治疗后长达1年没有残留疤痕或复发）。治疗失败定义为既存病变的数量和大小增加或不良副作用。最长治疗期为3个月。术后随访1年。结果表明，局部注射锑酸葡胺治愈率为41.7%，巴龙霉素治愈率为16.6%（P < 0.05）。葡甲胺组治疗失败率为39.7%，巴龙霉素组为72.9%（P < 0.05）。本研究表明，在治疗皮肤利什曼病中，病灶内注射锑酸葡甲胺上级优于局部外用巴龙霉素。
Ninety-six patients with a clinical and parasitological diagnosis of cutaneous leishmaniasis were recruited to a comparative randomized clinical trial evaluating the efficacy of topical paromomycin vs. weekly intralesional injections of meglumine antimoniate. The patients were randomly divided into two treatment groups: one group was treated with topical paromomycin ointment and the other with intralesional meglumine antimoniate. Treatment was continued in both groups until complete recovery occurred (defined as healing in less than 2 months with no residual scar or relapse for up to 1 year post treatment). Treatment failure was defined as an increase in the number and size of pre-existing lesions or untoward side-effects. The maximum treatment period was 3 months. The patients were followed up for 1 year. The results showed that intralesional meglumine antimoniate led to 41.7% complete recovery, However, topical paromomycin gave a lower cure rate of 16.6% (P < 0.05). Treatment failure was observed in 39.7% of the group receiving intralesional meglumine and in 72.9% of those on topical paromomycin (P < 0.05). This study indicates that intralesional meglumine antimoniate is superior to topical paromomycin in the treatment of cutaneous leishmaniasis.